Summary The Competition Authority of Bosnia & Herzegovina qualified the actions of the Health Insurance Office of the Sarajevo Canton, which excluded the pharmaceutical products of Novo Nordisk from the list of approved medicines sold to the insured under the national health insurance scheme, as anticompetitive practices under the national provisions similar to Article 81 EC. Facts Under the national health insurance scheme  in Bosnia & Herzegovina the government established the list of the approved medicines that can be sold to the insured and subsequently reimbursed from the funds administered by the regional health insurance offices. The administration also established the recommended prices at which the approved medicines can be sold to the insured. Where the
The Competition Authority of Bosnia & Herzegovina prosecutes anticompetitive agreements from the regional health insurance office (Novo Nordisk / Health Insurance Office of the Sarajevo Canton)
Access to this article is restricted to subscribers
Already Subscribed? Sign-in
Access to this article is restricted to subscribers.
Read one article for free
Sign-up to read this article for free and discover our services.